{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:39:09Z","timestamp":1790872749359,"version":"4.1.0"},"reference-count":32,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus prophylaxis in kidney transplant recipients (KTRs) is limited by post-transplant neutropenia and leukopenia (PTN\/PTL). Despite its clinical significance, the healthcare resource utilization (HCRU) related to PTN\/PTL remains poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate HCRU among KTRs taking valganciclovir during their first year post-transplant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using TriNetX Dataworks-USA, a federated, de-identified electronic medical record database, we identified adult KTRs who underwent their first kidney transplant from January 2012 to September 2020. All eligible patients were followed for 1 year. PTN\/PTL was defined as absolute neutrophil count less than 1000\/\u03bcL or white blood cell count less than 3500\/\u03bcL. Multivariable logistic\/Poisson regression models were used to assess the association between PTN\/PTL and various HCRU types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 8791 KTRs were identified, of whom 6219 (70.7%) developed PTN\/PTL at a mean of 5.7 months post-transplantation. Hospitalizations, rehospitalizations, emergency room visits, outpatient appointments, packed red blood cell transfusions, and granulocyte-colony stimulating factor administration were more prevalent among KTRs with PTN\/PTL (61.1% vs 49.5%, 24.5% vs 14.1%, 35.2% vs 28.9%, 30.4 vs 26.2 visits, 22.3% vs 17.6%, 23.4% vs 2.2%, respectively; P\u2009&lt;\u2009.001). Adjusted analyses confirmed that PTN\/PTL correlated with increased HCRU across all categories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>KTRs who developed PTN\/PTL had significantly higher HCRU. Further studies are needed to evaluate strategies addressing PTN\/PTL for KTRs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.125097","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T11:02:07Z","timestamp":1738148527000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare Resource Utilization Associated with Leukopenia and Neutropenia in Kidney Transplant Recipients Receiving Valganciclovir in the United States"],"prefix":"10.36469","volume":"12","author":[{"given":"Qinghua","family":"Li","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Turzhitsky","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Moise","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Jin","sequence":"additional","affiliation":[{"name":"TriNetX, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylen","family":"Brzozowski","sequence":"additional","affiliation":[{"name":"TriNetX, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kolobova","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.bjid.2016.08.007","article-title":"Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation","volume":"20","author":"C. H. Pinto","year":"2016","journal-title":"Braz J Infect Dis"},{"issue":"10","key":"ref2","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1016\/j.transproceed.2020.02.162","article-title":"Cytomegalovirus infection in postrenal transplant recipients: 18 years\u2019 experience from a tertiary referral center","volume":"52","author":"R. W. Minz","year":"2020","journal-title":"Transplant Proc"},{"issue":"28","key":"ref3","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.2174\/1381612826666200531152901","article-title":"Cytomegalovirus in solid organ transplant recipients: clinical updates, challenges, and future directions","volume":"26","author":"R. R. Razonable","year":"2020","journal-title":"Curr Pharm Des"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation","volume":"34","author":"A. P. Limaye","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"C. Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"R. R. Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"ref7","article-title":"Valcyte (valganciclovir hydrochloride) tablets prescribing information","author":"Genentech USA, Inc.","year":"2021"},{"key":"ref8","article-title":"Cytovene-IV (ganciclovir sodium) for injection prescribing information","author":"Genentech USA, Inc.","year":"2018"},{"issue":"4","key":"ref9","doi-asserted-by":"publisher","first-page":"e14583","DOI":"10.1111\/ctr.14583","article-title":"Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia","volume":"36","author":"S. Brar","year":"2022","journal-title":"Clin Transplant"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e14000","DOI":"10.1111\/tid.14000","article-title":"Burden of neutropenia and leukopenia among adult kidney transplant recipients: a systematic literature review of observational studies","volume":"25","author":"A. D. Raval","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"ref11","article-title":"Chronic kidney disease in the United States, 2021","author":"Centers for Disease Control and Prevention"},{"issue":"suppl 2","key":"ref12","doi-asserted-by":"publisher","first-page":"ofac492.284","DOI":"10.1093\/ofid\/ofac492.284","article-title":"Burden of post-transplant neutropenia and leukopenia among kidney transplant recipients: a multi-institutional real-world observational study","volume":"9","author":"A. D. Raval","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"ref13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"H. Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"11","key":"ref14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"H. Quan","year":"2005","journal-title":"Med Care"},{"issue":"5","key":"ref15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/pds.5204","article-title":"Validation of an International Classification of Disease, 10th revision coding adaptation for the Charlson Comorbidity Index in United States healthcare claims data","volume":"30","author":"J. Beyrer","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref16","series-title":"UpToDate","article-title":"Kidney transplantation in adults: induction immunosuppressive therapy","author":"J. Vella","year":"2024"},{"key":"ref17","series-title":"UpToDate","article-title":"Kidney transplantation in adults: maintenance immunosuppressive therapy","year":"2024"},{"key":"ref18","article-title":"Label for Bactrim (sulfamethoxazole and trimethoprim DS (double strength) tablets and tablets USP)","author":"US Food and Drug Administration"},{"issue":"suppl 1","key":"ref19","doi-asserted-by":"publisher","first-page":"S779","DOI":"10.1093\/ofid\/ofab466.1579","article-title":"Impact of cytomegalovirus prophylaxis on healthcare resource use and costs among kidney transplant recipients: a United States renal data system-Medicare linked database study","volume":"8","author":"A. D. Raval","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1399-0012.2008.00893.x","article-title":"Management of leukopenia in kidney and pancreas transplant recipients","volume":"22","author":"E. L. Hartmann","year":"2008","journal-title":"Clin Transplant"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fcell.2015.00018","article-title":"Blood disorders typically associated with renal transplantation","volume":"3","author":"Y. Yang","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"ref22","article-title":"Leading causes of death","author":"Centers for Disease Control and Prevention"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"10332","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus management in solid organ transplant recipients: a pre-COVID-19 survey from the working group of the European Society for Organ Transplantation","volume":"35","author":"P. A. Grossi","year":"2022","journal-title":"Transplant Int"},{"issue":"4","key":"ref24","doi-asserted-by":"publisher","first-page":"e14583","DOI":"10.1111\/ctr.14583","article-title":"Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia","volume":"36","author":"S. Brar","year":"2022","journal-title":"Clin Transplant"},{"issue":"7","key":"ref25","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/01.tp.0000257923.69422.4d","article-title":"Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction","volume":"83","author":"J. K. Walker","year":"2007","journal-title":"Transplantation"},{"issue":"11","key":"ref26","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.34067\/KID.0002472021","article-title":"Global perspective on kidney transplantation: United States","volume":"2","author":"J. H. Wang","year":"2021","journal-title":"Kidney360"},{"key":"ref27","article-title":"Organ Procurement and Transplantation Network National Data Reports, January 1, 1988 \u2013 March 31, 2023","author":"Organ Procurement and Transplantation Network"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/tid.12247","article-title":"Current characteristics and outcome of cytomegalovirus infections after kidney transplantation","volume":"16","author":"I. Helanter\u00e4","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"ref29","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1016\/j.transproceed.2015.08.011","article-title":"Risk factors of cytomegalovirus disease in kidney transplant recipients: a single-center study in Thailand","volume":"47","author":"T. Chiasakul","year":"2015","journal-title":"Transplant Proc"},{"issue":"6","key":"ref30","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.transproceed.2009.05.008","article-title":"Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients","volume":"41","author":"A. L. Corona-Nakamura","year":"2009","journal-title":"Transplant Proc"},{"issue":"6","key":"ref31","doi-asserted-by":"publisher","first-page":"e13106","DOI":"10.1111\/tid.13106","article-title":"Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy","volume":"21","author":"C. Felipe","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"suppl 2","key":"ref32","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/ndt\/gfh1079","article-title":"Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation","volume":"20","author":"M. J. Ricart","year":"2005","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/125097-healthcare-resource-utilization-associated-with-leukopenia-and-neutropenia-in-kidney-transplant-recipients-receiving-valganciclovir-in-the-united-stat","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:54:08Z","timestamp":1765914848000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/125097-healthcare-resource-utilization-associated-with-leukopenia-and-neutropenia-in-kidney-transplant-recipients-receiving-valganciclovir-in-the-united-stat"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.125097","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]}}}